19
May
2026
Biotech in the Balance: Saving a Strategic Industry. Jeremy Levin on The Long Run
Jeremy Levin is today’s guest on The Long Run. He is the executive chairman and founder of New York-based Ovid Therapeutics. He’s also a board member of the Biotechnology Innovation Organization, and a past chairman of the BIO board of directors. Jeremy has a new book out today, called “Biotech in the Balance: Saving a Strategic Industry in an Age... Read More
16
May
2026
Can AI-Powered Consumer Health Break Medicine’s Destructive Spiral?
This week’s Duke-Margolis Health Policy Conference (video here) left me feeling there’s a remarkable opportunity to leverage technology to dramatically improve healthcare — and there’s almost no chance of it happening within the current healthcare system. A number of speakers (including UCSF’s Bob Wachter, my WSJ review of his recent book here) were genuinely enthusiastic about the transformative possibility of... Read More
14
May
2026
FDA Boss Pushed Out, BMS Bets on China & Isomorphic’s Megaround
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
May
2026
AI in Practice
AI is here – everywhere it seems. How are we doing on translating this extraordinary promise into palpable value? Organizations As utopian AI “Accelerationists” have battled catastrophizing “Doomers” over competing visions of which eschaton is likely to be immanentized, a less visible but perhaps more consequential constituency has quietly focused on applying the still-evolving technology to the intractable problems of... Read More
7
May
2026
UCB Takes Over Candid, Odyssey’s IPO & Makary’s Rough Week
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
May
2026
Reflecting on a 35-Year Career in Biotech: Richard Pops on The Long Run
Richard Pops is the latest guest on The Long Run. Richard is the chairman and CEO of Alkermes. He’s one of the longest-serving biotech leaders ever, with a 35-year career at the helm of a single company. Rich is also one of the more issue-oriented and politically engaged industry leaders. As the head of a mid-sized biopharma company, he has... Read More
30
Apr
2026
An IPO Trio, Veradermics’ Hair Loss Win, & Erasca’s Rough Week
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Apr
2026
Biotech IPO Scorecard: Avalyn Joins Class of 2026
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Apr
2026
Oruka’s Psoriasis Contender, Intellia Passes Phase III, & Veradermics Roars
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Apr
2026
Lilly Buys In Vivo CAR-T, Psychedelics in the Fast Lane, Nektar Surges on Hair Loss Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Apr
2026
Small Molecule Synthesis Made Faster: Martin Burke on The Long Run
Martin Burke is today’s guest on The Long Run. Marty is a professor of chemistry, Director of the Molecule Maker Lab at the University of Illinois at Urbana-Champaign. He’s well known in the chemistry field for his pioneering work on blocc chemistry: iterative carbon-carbon bond formation that makes chemical synthesis faster, highly automated, and user-friendly. That was a big deal... Read More
20
Apr
2026
Progress for Sickle Cell Disease: Novo’s Oral Pill Passes Phase III
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Apr
2026
RevMed Nails RAS, Lilly Acquires CrossBridge, & IPOs Line Up
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Apr
2026
PhaseV Steps Up for Young Cancer Researchers
The Timmerman Traverse for Damon Runyon Cancer Research Foundation has a new major sponsor. PhaseV, the Boston-based company which provides AI/ML solutions to speed up and automate key aspects of clinical trials, has agreed to contribute $50,000 as the “Mt. Emerson” sponsor of this summer’s expedition in the High Sierras of California. This sponsorship could add up to much more.... Read More
13
Apr
2026
Big Monday: RevMed, Spyre, Ideaya, Allogene in the News
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Apr
2026
Gilead’s Deal Streak, Neurocrine Grows, & Stipple & Sidewinder Megarounds
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Apr
2026
Sidewinder Advances Bispecific ADCs for Cancer, Pockets $137M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Apr
2026
Computation, Chemistry & Culture For Drug Discovery: Abbas Kazimi on The Long Run
Abbas Kazimi is today’s guest on The Long Run. Abbas is the CEO of Boston-based Nimbus Therapeutics. It’s a privately held company that discovers and develops oral small molecule drugs. It does this through a combination of computational chemistry, medicinal chemistry, AI, and the combined effort of a small group of talented and hardworking people. Nimbus is probably best known... Read More
6
Apr
2026
Stipple Bio, Discovering New Cancer Drug Targets, Secures $100M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Apr
2026
The Unreasonable Effectiveness of Lifestyle
It wasn’t quite like the dream where you’re standing in front of an audience and suddenly realize you’re not wearing pants, but at a recent Harvard Business School function, I felt a flush of affinity. The occasion was an annual event for students in the Harvard life sciences MS/MBA program, designed to recognize the hard work of students and faculty,... Read More